Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 24Recruiting 18Terminated 11Active not recruiting 8Unknown 6Withdrawn 5Not yet recruiting 2Temporarily not available 1No longer available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

enzalutamide 2apalutamide 2Abiraterone Acetate 2radium Ra 223 dichloride 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms, Castration-Resistant × Clear all
NCT05191017 2022-08-05

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Nuvation Bio Inc.

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02866916 2021-01-20

PROSTIRNA

Institut Claudius Regaud

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03173859 2020-11-18

AERA

University of Athens

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02906605 2016-11-22

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Janssen Research & Development, LLC

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡